Medivir: Annual Report 2012
HUDDINGE, Sweden--(BUSINESS WIRE)-- Regulatory News:
Medivir (STO:MVIR-B) Annual Report 2012 is now available at the company's website: www.medivir.com.
Annual Report 2012 http://www.medivir.se/v4/images/pdf/2013/Medivir-ENG-web_0403.pdf
Medivir is an emerging research-based pharmaceutical company focused on infectious diseases.
Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company's key pipeline asset is simeprevir, a novel protease inhibitor in late phase III clinical development for hepatitis C that is being developed in collaboration with Janssen R&D Ireland.
Medivir has also a broad product portfolio with prescription pharmaceuticals in the Nordics.
For more information about Medivir AB, please visit the Company's website: www.medivir.com
Medivir is a collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C. We are passionate and uncompromising in our mission to develop and commercialize innovative pharmaceuticals that improve people's lives.
This information was brought to you by Cision http://news.cision.com
KEYWORDS: Europe Sweden
The article Medivir: Annual Report 2012 originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.